Evaluation of WLBU2 peptide and 3-O-octyl-sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia trachomatis.
Topical microbicides for prevention of sexually transmitted diseases (STDs) would be especially useful for women who are not able to persuade their partner(s) to take precautions. Many topical microbicides are in various stages of development, based on a variety of active ingredients. We investigated the in vitro activity of an engineered antimicrobial peptide (WLBU2) and a lipid (3-O-octyl-sn-glycerol [3-OG]) which could potentially be used as active ingredients in such a product. Using commercially available cytotoxicity reagents [Alamar Blue, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and lactate dehydrogenase (LDH)], we first determined the toxicity of WLBU2 and 3-OG to the host cells in our assay procedure and excluded toxic concentrations from further testing. To determine activity against Chlamydia trachomatis, we used an assay previously developed by our laboratory in which chlamydial elementary bodies (EBs) were exposed to microbicides prior to contact with epithelial cells: the minimum (microbi)cidal concentration (MCC) assay. To further simulate conditions of transmission, we carried out the same assay in the presence of a simulated vaginal fluid, a simulated seminal fluid, human serum albumin, and a range of pH values which might be found in the human vagina at the time of exposure. Last, we tested WLBU2 and 3-OG in combination to determine if adding them together resulted in synergistic activity. We found that WLBU2 and 3-OG both have excellent activity in vitro against C. trachomatis and significantly more activity when added together. The simulated fluids reduced activity, but the synergy seen is good evidence that they would be effective when combined in a microbicide formulation.
Skinner
M C
MC
Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
Kiselev
A O
AO
Isaacs
C E
CE
Mietzner
T A
TA
Montelaro
R C
RC
Lampe
M F
MF
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000891:Anti-Infective Agents, Local / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology*; D002460:Cell Line; D002692:Chlamydia trachomatis / Q000187:drug effects* / Q000502:physiology; D004357:Drug Synergism; D005260:Female; D005995:Glyceryl Ethers / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D010400:Penicillin G / Q000494:pharmacology; D011112:Polymyxin B / Q000494:pharmacology; D013778:Tetrazolium Salts / Q000737:chemistry; D013844:Thiazoles / Q000737:chemistry
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D023181:Antimicrobial Cationic Peptides; D005995:Glyceryl Ethers; D013778:Tetrazolium Salts; D013844:Thiazoles; C520840:WLBU2 peptide; D007770:L-Lactate Dehydrogenase; C022616:thiazolyl blue; D011112:Polymyxin B; D010400:Penicillin G